Dr Lal PathLabs Q1 FY27 Revenue ₹798 Cr, Up 19.1%
Dr Lal PathLabs Limited announced its un-audited financial results for the quarter ended June 30, 2026. The company reported a consolidated revenue of ₹798 Cr, marking a 19.1% increase year-on-year. EBITDA grew by 28.7% to ₹247 Cr with a margin of 31.0%, and Profit After Tax (PAT) stood at ₹170 Cr, a 27.2% increase, with a margin of 21.4%. The company also declared an interim dividend of 50% (₹5 per share). Key strategic moves include the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, for up to GHS 45.6 million, and a 30% stake in Neuome Technologies Private Limited for up to ₹3.5 Cr. Cash and cash equivalents were reported at ₹1,693 Cr as of June 30, 2026.
Key Highlights
- Revenue surged 19.1% to ₹798 Cr in Q1 FY27.
- EBITDA increased 28.7% to ₹247 Cr, with margins at 31.0%.
- PAT grew 27.2% to ₹170 Cr, maintaining a 21.4% margin.
- Declared interim dividend of 50% (₹5 per share).
- Acquired 80% stake in Sunshine Healthcare, Ghana.
Price Impact
More from LALPATHLAB
Dr. Lal PathLabs Independent Director Tenure Ends
Dr. Lal PathLabs Board Approves Interim Dividend, Stock Options, and Acquisitions
Dr. Lal PathLabs Board Approves Interim Dividend, Stock Options, and Acquisitions